a 0-3 scale, but it does not include the distal interphalangeal (DIP) joints of the feet. The Ritchie index demonstrated more observer-related variation than did the ACR joint count in RA. The 28-joint count is a reduced joint count which includes both shoulders, elbows and wrists, all metacarpalphalangeal joints, all proximal interphalangeal joints of the hands, and both knees. It has been studied in RA, but it has not been validated in PsA. The 28-joint count could not be appropriate for PsA: 1) more than 50% of the patients have inflammation of the DIP joints; 2) in some patients arthritic manifestations are restricted to DIP joints; 3) foot involvement is common in PsA.
Measures used to assess peripheral joint disease in recent clinical trials in PsA
Psoriatic Arthritis Response Criteria (PsARC), ACR response criteria (20, 50 e 70%) and EULAR response criteria based on Disease Activity Score (DAS) were used to assess joint disease in recent clinical trials in PsA (13) (14) (15) (16) (17) (18) . These response measures include: assessment of tender and swollen joints and patient -and physician -derived scores. They successfully distinguished drug-treated from placebo-treated patients.
Psoriatic Arthritis Response Criteria were developed by Clegg et al for the study of sulfasalazine in PsA (13 In PsA clinical trials the total number of joints counted was increased to 78 for tenderness and 76 for swelling, including the 66 or 68 joints routinely evaluated in an ACR joint count plus 10 additional joints often involved in PsA (the first carpometcarpal and the DIP joints of the toes). These criteria were included as outcome measures (primary or secondary) in recent PsA clinical trials and the differences observed in the responses between drug-and placebo-treated patients indicate that ACR response criteria for RA have validity in PsA trials (Table II) In conclusion, based on their ability to distinguish between drug-treated and placebo-treated patients, the ACR, PsARC, and EULAR response criteria for outcome assessment in RA appear to be valid in the assessment of peripheral arthritis in PsA.
SPINAL DISEASE
Spondylitis occurs in ~ 40% of patients with PsA, but it is less severe than that of AS. Therefore, it is possible that measures of axial disease originally developed for AS may not be sufficiently sensitive to change or accurate for use in PsA. ASAS response criteria are a clinically valid, easy-to-use measure of short term improvement in AS validated in clinical trials (19) . ASAS 20 or 40% response criteria could be used to measure axial PsA disease activity and to assess therapeutic response, but they must be validated in this condition. ASAS 20 improvement criteria include: improvement of ≥20% and ≥10 units in at least 3 of the following 4 domains: patient global assessment, pain, function, inflammation + no worsening of ≥20% and ≥10 units in the remaining domain.
DACTYLITIS
Dactylitis occurs in 16-48% of cases of PsA (22) . Acute dactylitis has been shown to be a clinical indicator of disease severity. However, chronic, nontender diffuse dactylitic swelling may be less clini-cally significant. An instrument suitable for quantifying psoriatic dactylitis must be able to measure the amount of swelling and distinguish tender from nontender digits. At the moment, there are no validated, sensitive measure for dactylitis. In our practice we use a 0-2 scale (0 = none, 1 = present but minimal, 2 = present and maximal) and we count all 20 digits where dactylitis is present (the joints in that digit are not scored separately). Recently, a new method for quantifying dactylitis based on digital circumference and tenderness has been described with a good inter and intraobserver reliability (23) .
Measures used to assess dactylitis in recent clinical trials in PsA
A simple scoring of present or absent dactylitis was used in the IMPACT trial with infliximab (15), in which statistically significant improvement of dactylitis was demonstrated in the infliximab group. Dactylitis was evaluated using a 0-3 scale, based on the clinician's judgement of relative severity, for each digit of the hand and toes in the trial with adalimumab (18) . In this trial dactylitis improved, but the changes did not achieve statistical significance comparing adalimumab treatment group to placebo group.
ENTHESITIS
Two enthesitis measures have been developed for spondyloarthropathies: the Mander index and the Maastricht Ankylosing Spondylitis Enthesis Score (MASES) (24, 25) . The Mander index, which includes 66 sites, has been considered cumbersome because of the large number of sites assessed. The MASES index, which includes 13 anatomic sites is more simple, has been validates in patients with AS, but it has not yet been assessed in PsA trials.
Measures used to assess enthesitis in recent clinical trials in PsA
Enthesitis was defined as present or absent on the plantar fascia and insertion of the Achilles tendons bilaterally. Enthesitis was significantly improved with infliximab treatment but not with adalimumab treatment compared to placebo (15, 18) .
MEASURES OF FUNCTION AND DISABILITY
The following measures of function and disability were validated in PsA: the Health Assessment Questionnaire (HAQ) which assesses function related to arthritis and the Medical Outcomes Study Short-Form 36 (SF-36) which is a generic quality of life instrument (11) .
A new quality of life measure (PsAQol) has been recently developed for PsA but it requires validation (26) . The Health Assessment Questionnaire was developed by Fries et al for the assessment of disability in patients with RA (27) . HAQ focuses on physical disability (8 scales) and pain. A modification of the HAQ for spondyloarthropaties (HAQ-S) was also developed, which includes 2 spinal domains. A further modification, HAQ for psoriasis (HAQ-SK) was also studied in PsA patients. Both HAQ and HAQ-S were tested in PsA patients, both correlated with disease activity, and their scores were almost identical. HAQ has been used in several PsA therapy trials (11) . SF-36 is a generic health assessment questionnaire, which has been studied in a number of chronic diseases including rheumatic conditions. SF-36 assesses 8 domains: physical functioning, pain, vitality, social functioning, psychological functioning, general health perceptions, and role limitations due to physical and emotional problems. SF-36 has been validated in PsA. In PsA SF-36 was equally or more responsive than HAQ to short term changes in perceived health status and inflammatory disease activity. SF-36 has been used in several PsA therapy trials (11) .
Measures used to assess function and disability in recent clinical trials in PsA
Recently randomized controlled trials with anti-TNF agents and leflunomide demonstrated significant reductions in HAQ scores in the patient group treated with the active drug compared to placebo group. SF-36 has also demonstrated significant improvement in recent PsA therapeutic trials (15) (16) (17) (18) .
